CD59 and B-cell chronic lymphocytic leukemia: Three of the non-responders to the rituximab plus CFH mAb combination (patients #6, 8, and 10) had a relatively low to moderate level of CD20 and a relatively high level of CD59, suggesting that these patients’ B-CLL cells had at least two potential mechanisms of resistance.